Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Standardized visual overlays enhance laparoscopic instruction: A mixed-methods evaluation.

American journal of surgery·2026

Same author

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Future oncology (London, England)·2026

Same author

Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer risk.

BMJ open·2026

Same author

Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.

Current oncology (Toronto, Ont.)·2026

Same author

A patient-derived ccRCC model that retains native stromal features to assess fibrosis-driven personalized therapeutic response.

Scientific reports·2026

Same author

Genetic testing practices among specialist physicians who treat prostate cancer: Updated survey of Canadian practitioners.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2026

Search research articles

Related Experiment Video

Updated: Aug 4, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.

Ronald Kool¹, Gautier Marcq², Rodney H Breau³

¹Division of Urology, McGill University Health Center, Montreal, Canada; Department of Abdominal Surgery, Erasto Gaertner Cancer Center, Curitiba, Brazil.

European Urology Oncology

|April 2, 2023

Summary

Radiation therapy (RT) offers a complete response in most muscle-invasive bladder cancer (MIBC) patients. Further trials are needed to validate the benefits of neoadjuvant chemotherapy (NAC) and whole-pelvis RT.

Keywords:

Bladder cancer Radiotherapy Urinary tract neoplasm

More Related Videos

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Related Experiment Videos

Last Updated: Aug 4, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Area of Science:

Oncology
Radiation Oncology
Urologic Oncology

Background:

Radiation therapy (RT) serves as a key alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
Understanding predictors of treatment success is crucial for optimizing bladder preservation strategies.

Purpose of the Study:

To identify prognostic factors associated with complete response (CR) and survival outcomes in patients with MIBC treated with curative-intent RT.
To analyze the impact of neoadjuvant chemotherapy (NAC) and whole-pelvis RT on treatment efficacy.

Main Methods:

A multicenter retrospective study included 864 patients with nonmetastatic MIBC undergoing curative-intent RT between 2002 and 2018.
Regression models were employed to assess factors influencing CR, cancer-specific survival (CSS), and overall survival (OS).

Main Results:

A CR was achieved in 78% of patients. Higher cT stage and hydronephrosis were associated with lower CR rates.
Five-year CSS and OS rates were 63% and 49%, respectively. Factors like advanced age, hydronephrosis, and worse performance status impacted OS.
Neoadjuvant chemotherapy (NAC) and whole-pelvis RT showed associations with improved CSS and OS, though study limitations include treatment protocol heterogeneity.

Conclusions:

Curative-intent RT achieves a high CR rate in MIBC patients opting for bladder preservation.
Prospective validation is required to confirm the benefits of NAC and whole-pelvis RT in MIBC treatment.